



Hyperinsulinism Around the World:- Australia



Dr Louise Conwell, Dr Ristan Greer
on behalf of Congenital Hyperinsulinism Group, Brisbane

Congenital Hyperinsulinism Group


Brisbane, Australia



Congenital Hyperinsulinism Group Brisbane, Australia



Paediatric Endocrinology Centres in Australia



Royal Children's Hospital



Mater Children's Hospital



Queensland Children's Hospital opening 2014



School of Medicine University of Queensland



Children's Health Services

Queensland Health

Congenital Hyperinsulinism Group Brisbane, Australia

- Paediatric Endocrinologists, Royal and Mater Children's Hospitals
 - Dr Louise S. Conwell
 - A/Prof Andrew Cotterill
 - Dr Mark Harris
 - A/Prof Gary Leong
 - Prof Jennifer Batch
 - Dr Sarah McMahon
 - Dr Michelle Jack (previous research)

Children's Health Services

Queensland Health



Queensland Government

Congenital Hyperinsulinism Group

Brisbane, Australia

- Clinical Researcher, Queensland Children's Medical Research Institute, University of Queensland
 - Dr Ristan Greer
- Department of Nuclear Medicine, Radioisotope Laboratory and Queensland PET Service, Royal Brisbane and Women's Hospital
 - Prof David MacFarlane, Dr Frank Fiumara
 - Louise Campbell
 - Damion Stimson
 - Dr Matthew Griffiths

Children's Health Services

Queensland Health



Queensland Government

Congenital Hyperinsulinism Group Brisbane, Australia

- Paediatric Surgeons, Royal and Mater Children's Hospitals
 - Dr Rosslyn Walker
 - Dr Kelvin Choo
- Pathology Departments, Mater Children's Hospitals
 - Dr David Cowley
 - Ivan McGowan
- Adult Endocrinologist and Genetics Researcher, Royal Brisbane and Women's Hospital, University of Queensland
 - A/Prof Emma Duncan

Children's Health Services

Queensland Health



Queensland Government

Congenital Hyperinsulinism Group Brisbane, Australia

- Previous research
- Australian Paediatric Surveillance Unit Survey 2005-6
- ^{18}F -DOPA PET/CT imaging available - 2010
- Development of a clinical national framework for care of infants and children with hyperinsulinism of infancy
- Genetics Research

Children's Health Services

Queensland Health



Queensland Government

Previous Research

- Genetic diagnosis compared to clinical features
- Outcome in Australian children with hyperinsulinism of infancy
 - Early rather than late extensive surgery in severe cases lowers the risk of diabetes
- Histological findings in persistent hyperinsulinaemic hypoglycaemia of infancy: Australian experience

Australian Paediatric Surveillance Unit Survey 2005-6

Issues identified:-

- Few with definitive diagnosis (channelopathy/enzymopathy)
- Importance of clinician awareness
- High proportion ongoing diazoxide need


Children's Health Services

Queensland Health




Queensland Government

18F-DOPA PET/CT imaging available in Australia (Southern Hemisphere) from 2010




- Journey to PET / CT
 - Addiction research – dopamine function in brain nerves in early abstinence from alcohol
 - Brain tumour assessment (glioma)
 - Movement disorders
 - Parkinson's disease
 - Neuroendocrine disorders
 - Congenital hyperinsulinism opportunistic!!





18F-DOPA PET/CT imaging available in Australia (Southern Hemisphere) from 2010

- 5 cases to date (Poster at Medical Conference)
 - Age 5 months to 35 months
 - 4 diffuse / 1 focal
 - No adverse events



Focal uptake in pancreatic head

Cyclotron, Radiosynthesiser, PET / CT



18F-DOPA PET/CT imaging in Congenital Hyperinsulinism – first 12 months of the Australian experience

Louise S Conwell^{1,2}, Ristan M Greer², Rosslyn M Walker³, Frank Fiumara⁴, Louise Campbell⁴, Mark Harris⁵, Andrew M Cotterill⁵

¹ Department of Endocrinology and Diabetes, Royal Children's Hospital, Brisbane, Queensland

² Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Queensland

³ Departments of Surgery, Royal Children's Hospital and Mater Children's Hospital, Brisbane, Queensland

⁴ Department of Nuclear Medicine and Queensland PET Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland

⁵ Department of Paediatric Endocrinology and Diabetes, Mater Children's Hospital, Brisbane, Queensland

Background

- 18F-DOPA PET/CT became available in Brisbane, Australia, in early 2010
- Only facility in the southern hemisphere
- Enables pre-operative distinction between focal and diffuse forms of Congenital Hyperinsulinism of Infancy (CHI)

Objective

- Review the cases of 18F-DOPA in CHI since imaging became available

Methods

- 18F-DOPA prepared by the electrophilic fluorination method
- Scan under GA
- Case records reviewed for
 - Clinical details
 - Metabolic and genetic investigations
 - 18F-DOPA result
 - Histology if surgery performed
 - Clinical outcome




PET/CT Scanner with ancillary anaesthetic equipment.

Results

- Five PET/CT scans performed
- No adverse events

Case 1. A scan was performed when the male infant (paternal mutation KCNJ11) had continuing hypoglycaemia post partial pancreatectomy at 5 months. Diffuse disease was confirmed by PET/CT and a near-total resection at 7months. He is well at 11 months with no medication.


Case 1
diffuse



Case 2. A male, (genetics not available) had a scan at 35 months in the context of high-dose diazoxide, with glucose instability. PET/CT suggested diffuse disease, confirmed by histology following pancreatic tail and body resection.

Surgery resulted in decreased diazoxide requirement and improved metabolic stability.


Case 2
diffuse



Case 3. A female (paternal mutation ABCC8) on multiple medical therapies was scanned at 6 months showing a focal lesion, confirmed at resection. She is well at 17 months with no medication.

In this case, PET/CT avoided multiple operations and lifelong diabetes, and a decreased time at risk of hypoglycaemia and neurological damage.

Case 3
focal



Case 4. A male (paternal mutation ABCC8) with continuing diazoxide had a scan at 4years showing diffuse uptake.

His parents were reassured of the need for continuing diazoxide and lack of indication for pancreatectomy.

Case 5. A female, (GLUD-1 mutation identified) had a scan at 14 months of age, 10 days after presentation with seizures and a requirement for intensive medical management. The scan showed diffuse uptake.

This baby was controlled on diazoxide after initial metabolic instability.

Conclusions

PET/CT has been safe and useful in planning surgery for infants and children with CHI, correctly identifying both focal and diffuse disease. Children undergoing surgery should undergo PET/CT to confirm or distinguish focal and diffuse disease and facilitate surgical planning.

A clinical national framework for care of infants and children with hyperinsulinism of infancy (HI):- integrating

- (i) genetics
- (ii) 18F-DOPA PET/CT
- (iii) medical
- and/or (iv) surgical management

for best patient outcome.

Acknowledgements

- Royal Children's Hospital Foundation, Brisbane
- Queensland Children's Medical Research Institute

Children's Health Services

Queensland Health



Queensland Government

Genetics Research:-

“Evaluating the efficacy of next generation DNA sequencing in the diagnosis of disorders of beta cell function”.

Potential benefits

- Faster, less expensive
- Identify new mutations

PhD Project

- Dr Stephanie Johnson
- A/Prof E Duncan, Dr M Harris, Dr L Conwell

Funding Acknowledgements

- University of Queensland
- Pfizer Australian Paediatric Endocrine Care
- Royal Brisbane and Women's Hospital

